PHPN Mentor Program Provides Valuable Lessons to Health Care Professionals

2018-09-21T20:52:19+00:00 September 21st, 2018|

The diagnosis of pulmonary hypertension (PH) is overwhelming in patients’ and caregivers’ lives. It also can prove challenging to health care professionals new to the field. Before health care professionals were experts, they were studying and training underneath their mentors to learn quality patient care and implement best practices. The Pulmonary Hypertension Association’s (PHA) PH

Examination of PHAR Data Shows Few Patients are Referred to Palliative Care

2018-08-31T15:42:34+00:00 August 31st, 2018|

Although treatment options for WHO Group 1 PH (pulmonary arterial hypertension, or PAH) have increased over the past few decades, symptom severity and quality of life still impose significant burden on patients. Palliative care – often confused with hospice care – is goal-oriented care for patients with chronic illnesses that help to balance life-saving

FDA Approves Generic Version of Adcirca®; Additional Approvals May Come Soon

2018-08-21T13:45:25+00:00 August 17th, 2018|

The Pulmonary Hypertension Association (PHA) recently learned that the Food and Drug Administration (FDA) has approved a generic version of tadalafil, the pulmonary arterial hypertension (PAH)-targeted therapy sold as Adcirca®. Availability of the generic therapy for patients remains to-be-determined. PHA also has been advised that generic versions of other PAH-targeted therapies may become available soon.

Latest PH Roundtable Focuses on Palliative Care, the Misconceptions and Benefits

2018-08-17T21:44:59+00:00 August 17th, 2018|

The latest issue of Advances in Pulmonary Hypertension focuses on palliative care as an integral component of treating people with pulmonary hypertension (PH). Many people have the misconception that palliative care relates solely to hospice care, which is end of life care and only one part of palliative care. Palliative care, named from the

Bellerophon Therapeutics Announces Interim Results of Nitric Oxide Clinical Trial in Pulmonary Arterial Hypertension

2018-08-10T21:02:47+00:00 August 10th, 2018|

Bellerophon Therapeutics announced this week that its Phase 3 clinical trial of pulsatile inhaled nitric oxide (iNO) for World Health Organization (WHO) Group 1 PH (pulmonary arterial hypertension, or PAH) was discontinued for futility August 7, after a planned interim analysis. Nitric oxide (NO) is a molecule naturally produced in the body that helps many

Fatigue: Under-Recognized and Unaddressed in PH

2018-08-10T21:01:47+00:00 August 10th, 2018|

by Phyllis Hanlon, Contributing Writer Symptoms that are commonly experienced by people with pulmonary hypertension (PH) — such as shortness of breath, light-headedness, chest pain, swelling and fatigue — can negatively impact their quality of life. Fatigue – lack of energy or an increased sense of effort with routine tasks – is reported in

Learning to Live Your Best Life: Join PHA on the Road in 2018

2018-08-03T21:26:13+00:00 August 3rd, 2018|

The Pulmonary Hypertension Association (PHA) announces the dates and cities for two PHA on the Road: PH Patients and Families Education Forums for 2018. Forums are scheduled in Long Beach, Calif., September 29, and Milwaukee, October 27. PHA on the Road, a program of the PHA Medical Education Fund,* provides a unique opportunity for

United Therapeutics Receives FDA Approval for the Implantable System for Remodulin®

2018-08-03T21:23:00+00:00 August 3rd, 2018|

United Therapeutics Corporation announced July 31 that it had received approval from the Food and Drug Administration (FDA) for Remodulin® (treprostinil) to be used in the Implantable System for Remodulin® for patients with WHO Group 1 PH (pulmonary arterial hypertension, or PAH). Development of the Implantable System for Remodulin® resulted from a collaboration between United

2018 PHA Conference Session Provided Insights into PH Advances in China

2018-08-03T21:27:53+00:00 August 3rd, 2018|

By Huan Huang, cofounder and director of iSEEKPH Hope Center and presenter at PHA’s 2018 International PH Conference and Scientific Sessions In the treatment of pulmonary hypertension (PH), China has the largest population of people with PH in one country and no Chinese-made therapies. However, things have begun to change. Since last year, the China

Participation in PHA Conference Opens Doors for Northwestern University Researcher

2018-07-27T17:41:33+00:00 July 27th, 2018|

Zhiyu Dai, Ph.D., a researcher at Northwestern University and assistant professor of research at Northwestern University Feinberg School of Medicine in Chicago, has presented his work during the past two Pulmonary Hypertension Association (PHA) International PH Conference and Scientific Sessions. He also has been awarded top abstract in basic science by the Scientific Sessions